Home
EN / FR

Home

ABOUT CELYAD ONCOLOGY

Celyad Oncology is a clinical-stage biotechnology company focused on the discovery and development of chimeric antigen receptor T cell (CAR T) therapies for cancer

More Info About Celyad ONCOLOGY

Latest News

Celyad Oncology Reports First Half 2022 Financial Results and Recent Business Highlights

August 5, 2022
READ THE PRESS RELEASE

Celyad Oncology Announces FDA Lifts Clinical Hold of CYAD-101-002 Phase 1b Trial

August 1, 2022
READ THE PRESS RELEASE

Celyad Oncology to Announce First Half 2022 Financial Results and Host Conference Call

July 28, 2022
READ THE PRESS RELEASE

Celyad Oncology Announces Leadership Updates

June 24, 2022
READ THE PRESS RELEASE

Information on the Total Number of Voting Rights and Shares (Article 15 of the Law of 2 May 2007)

May 31, 2022
READ THE PRESS RELEASE

Celyad Oncology to Present at the H.C. Wainwright Global Investment Conference

May 17, 2022
READ THE PRESS RELEASE

Celyad Oncology Announces First Quarter 2022 Financial Results and Recent Business Highlights

May 5, 2022
READ THE PRESS RELEASE

Letter to Shareholders – March 2022

March 25, 2022
READ THE PRESS RELEASE

Celyad Oncology Reports Full Year 2021 Financial Results and Recent Business Highlights

March 24, 2022
READ THE PRESS RELEASE

Celyad Oncology to Announce Full Year 2021 Financial Results and Host Conference Call

March 17, 2022
READ THE PRESS RELEASE
Discover All News

Our SCIENCE

At Celyad Oncology, we are pursuing next-generation cellular immunotherapies by applying our broad understanding of immunology, novel technology platforms and modular design approach to drug discovery.

Read More About Our SCIENCE

Novel CAR T Immunotherapies

Advancing both allogeneic and autologous CAR T therapy candidates for the treatment of cancer

View Pipeline
Getty_488635681_lowres-1

Celyad Oncology @celyadsa ·
15 Aug

#DYK that by following a few recommendations, you can potentially reduce your risk of developing a serious form of cancer? Read more tips from the @MayoClinic here: https://buff.ly/2zaV9Xv

Twitter 1559179111125450753
Celyad Oncology @celyadsa ·
11 Aug

Excited to be included in the annual @medicine_maker Biopharma Trends 2022 report. Our CMO Dr. Charles Morris discusses future trends in the biopharma and #oncology industry, including thoughts on the future of CAR T. Read here (starting on page 22!): https://buff.ly/3C0lXbU

Twitter 1557755352921378818

View All

Stay informed about the latest news!

Sign up FOR our newsletter

By clicking on “send”, you consent that your personal data will be processed by us in order to send you our newsletter. You have the right to access, rectify, erase your data, to restrict the processing and the right to withdraw your consent at any time. You can find more information on how we process your data in our Privacy Policy.